Verification Opinion
China International Capital Corporation (hereinafter referred to as "CICC" or "Sponsor") is the sponsor for the initial public offering and continuous supervision of Beijing Ruimait Medical Technology Co., Ltd. (hereinafter referred to as "Ruimait" or "Company"). In accordance with relevant laws, regulations, and business rules, CICC has conducted a thorough and prudent verification of Ruimait's use of excess funds for new project construction. The specific situation is as follows:
1. Basic Situation of Fundraising
With the approval of the China Securities Regulatory Commission regarding the initial public offering of Beijing Yihe Jiaye Medical Technology Co., Ltd., and with the consent of the Shenzhen Stock Exchange, the company issued 16 million shares of RMB ordinary shares (A shares) at a par value of 1.00 RMB per share, with an issuance price of 119.88 RMB per share. The total amount raised was 1,918.08 million RMB, and after deducting issuance costs (excluding the previously recognized loss of 3.2075 million RMB), the net amount raised was 1,738.2674 million RMB. The raised funds were transferred to the company's designated account on October 25, 2022. Tianjian Accounting Firm (Special General Partnership) verified the raised funds and issued a verification report on October 25, 2022. After the funds were received, the company stored the raised funds in a special account and signed a regulatory agreement with the sponsor and the bank holding the raised funds.
2. Investment Project Situation
As of December 31, 2025, the usage of the raised funds is as follows:
| No. | Investment Project Name | Proposed Investment Amount (10,000 RMB) | Actual Investment Amount (10,000 RMB) | Fund Usage Progress (%) |
|---|---|---|---|---|
| 1 | Production of 300,000 ventilators and 3.5 million sets of accessories | 190,000 | 60,225 | 31.70 |
| 2 | Marketing network and brand building project | 156,955 | 83,408 | 53.14 |
| 3 | Medical equipment R&D center project | 191,043 | 165,848 | 86.81 |
| 4 | Supplementing working capital | 200,000 | 180,731 | 90.37 |
| Total | 737,997.6 | 490,021.9 | 66.42 |
3. Use of Excess Funds
On November 17, 2022, the company held the 11th meeting of the second board of directors and the 9th meeting of the second supervisory board, where it approved the proposal to use part of the idle raised funds for cash management. The board agreed to use up to 1.738 billion RMB of temporarily idle raised funds (including excess funds) for cash management, with a maximum investment product term of no more than 12 months. The resolution is valid for 12 months from the date of approval by the board. Within the aforementioned limit and validity period, the funds can be recycled. The company plans to purchase safe, liquid, and principal-protected products such as structured deposits and large certificates of deposit, with purchase channels being commercial banks and securities companies.